image
Healthcare - Medical - Devices - NASDAQ - US
$ 5.95
-7.32 %
$ 766 M
Market Cap
-74.37
P/E
1. INTRINSIC VALUE

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils.[ Read More ]

The intrinsic value of one CTKB stock under the base case scenario is HIDDEN Compared to the current market price of 5.95 USD, Cytek Biosciences, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CTKB

image
FINANCIALS
193 M REVENUE
17.67%
-27.8 M OPERATING INCOME
-1424.92%
-12.1 M NET INCOME
-489.05%
5.28 M OPERATING CASH FLOW
143.18%
-93.9 M INVESTING CASH FLOW
-67.94%
-41.8 M FINANCING CASH FLOW
-758.43%
51.5 M REVENUE
10.47%
-4.25 M OPERATING INCOME
50.18%
940 K NET INCOME
109.01%
13.2 M OPERATING CASH FLOW
113.10%
-15.8 M INVESTING CASH FLOW
-781.85%
-12.1 M FINANCING CASH FLOW
-606.25%
Balance Sheet Decomposition Cytek Biosciences, Inc.
image
Current Assets 392 M
Cash & Short-Term Investments 262 M
Receivables 56.1 M
Other Current Assets 73.5 M
Non-Current Assets 102 M
Long-Term Investments 1.6 M
PP&E 29.3 M
Other Non-Current Assets 71.5 M
Current Liabilities 56.2 M
Accounts Payable 3.03 M
Short-Term Debt 3.01 M
Other Current Liabilities 50.2 M
Non-Current Liabilities 45.2 M
Long-Term Debt 11.1 M
Other Non-Current Liabilities 34 M
EFFICIENCY
Earnings Waterfall Cytek Biosciences, Inc.
image
Revenue 193 M
Cost Of Revenue 83.6 M
Gross Profit 109 M
Operating Expenses 137 M
Operating Income -27.8 M
Other Expenses -15.7 M
Net Income -12.1 M
RATIOS
56.69% GROSS MARGIN
56.69%
-14.43% OPERATING MARGIN
-14.43%
-6.29% NET MARGIN
-6.29%
-3.09% ROE
-3.09%
-2.46% ROA
-2.46%
-5.45% ROIC
-5.45%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Cytek Biosciences, Inc.
image
Net Income -12.1 M
Depreciation & Amortization 9.23 M
Capital Expenditures -4.83 M
Stock-Based Compensation 22 M
Change in Working Capital -10.5 M
Others -9.02 M
Free Cash Flow 454 K
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Cytek Biosciences, Inc.
image
Wall Street analysts predict an average 1-year price target for CTKB of $11.2 , with forecasts ranging from a low of $8.5 to a high of $16 .
CTKB Lowest Price Target Wall Street Target
8.5 USD 42.86%
CTKB Average Price Target Wall Street Target
11.2 USD 89.08%
CTKB Highest Price Target Wall Street Target
16 USD 168.91%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Cytek Biosciences, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
400 K USD 1
9-12 MONTHS
359 K USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7 months ago
Apr 19, 2024
Sell 117 K USD
Yan Ming
CHIEF TECHNOLOGY OFFICER
- 20000
5.87 USD
7 months ago
Apr 09, 2024
Sell 10.5 K USD
Yan Ming
CHIEF TECHNOLOGY OFFICER
- 1500
7 USD
7 months ago
Apr 09, 2024
Sell 2.8 K USD
Yan Ming
CHIEF TECHNOLOGY OFFICER
- 400
7.01 USD
8 months ago
Mar 18, 2024
Sell 135 K USD
Yan Ming
CHIEF TECHNOLOGY OFFICER
- 20000
6.77 USD
8 months ago
Mar 19, 2024
Sell 134 K USD
Yan Ming
CHIEF TECHNOLOGY OFFICER
- 20000
6.71 USD
10 months ago
Dec 26, 2023
Sell 28.5 K USD
Jeanmonod Patrik
Chief Financial Officer
- 3000
9.5 USD
11 months ago
Dec 19, 2023
Sell 189 K USD
Yan Ming
Chief Technology Officer
- 20000
9.43 USD
11 months ago
Nov 24, 2023
Sell 20.8 K USD
Jeanmonod Patrik
Chief Financial Officer
- 3000
6.94 USD
11 months ago
Nov 20, 2023
Sell 121 K USD
Yan Ming
Chief Technology Officer
- 20000
6.03 USD
1 year ago
Nov 07, 2023
Sell 86.8 K USD
Jiang Wenbin
President and CEO
- 20000
4.34 USD
1 year ago
Oct 24, 2023
Sell 14 K USD
Jeanmonod Patrik
Chief Financial Officer
- 3000
4.68 USD
1 year ago
Oct 19, 2023
Sell 96 K USD
Yan Ming
Chief Technology Officer
- 20000
4.8 USD
1 year ago
Oct 09, 2023
Sell 107 K USD
Jiang Wenbin
President and CEO
- 20000
5.33 USD
1 year ago
Sep 25, 2023
Sell 19.1 K USD
Jeanmonod Patrik
Chief Financial Officer
- 3000
6.38 USD
1 year ago
Sep 19, 2023
Sell 130 K USD
Yan Ming
Chief Technology Officer
- 20000
6.49 USD
1 year ago
Sep 07, 2023
Sell 137 K USD
Jiang Wenbin
President and CEO
- 20000
6.83 USD
1 year ago
Aug 24, 2023
Sell 23.1 K USD
Jeanmonod Patrik
Chief Financial Officer
- 3000
7.69 USD
1 year ago
Aug 21, 2023
Sell 161 K USD
Yan Ming
Chief Technology Officer
- 20000
8.07 USD
1 year ago
Aug 07, 2023
Sell 181 K USD
Jiang Wenbin
President and CEO
- 20000
9.04 USD
1 year ago
Jul 24, 2023
Sell 27.5 K USD
Jeanmonod Patrik
Chief Financial Officer
- 3000
9.17 USD
1 year ago
Jul 19, 2023
Sell 175 K USD
Yan Ming
Chief Technology Officer
- 20000
8.76 USD
1 year ago
Jul 07, 2023
Sell 170 K USD
Jiang Wenbin
President and CEO
- 20000
8.48 USD
1 year ago
Jun 26, 2023
Sell 23.9 K USD
Jeanmonod Patrik
Chief Financial Officer
- 3000
7.96 USD
1 year ago
Jun 20, 2023
Sell 164 K USD
Yan Ming
Chief Technology Officer
- 20000
8.18 USD
1 year ago
Jun 07, 2023
Sell 165 K USD
Jiang Wenbin
President and CEO
- 20000
8.23 USD
1 year ago
May 24, 2023
Sell 23.3 K USD
Jeanmonod Patrik
Chief Financial Officer
- 3000
7.76 USD
1 year ago
May 19, 2023
Sell 144 K USD
Yan Ming
Chief Technology Officer
- 20000
7.19 USD
1 year ago
May 08, 2023
Sell 231 K USD
Jiang Wenbin
President and CEO
- 20000
11.55 USD
1 year ago
Apr 24, 2023
Sell 30.7 K USD
Jeanmonod Patrik
Chief Financial Officer
- 3000
10.24 USD
1 year ago
Apr 19, 2023
Sell 194 K USD
Yan Ming
Chief Technology Officer
- 20000
9.71 USD
1 year ago
Apr 10, 2023
Sell 178 K USD
Jiang Wenbin
President and CEO
- 20000
8.88 USD
1 year ago
Mar 24, 2023
Sell 25 K USD
Jeanmonod Patrik
Chief Financial Officer
- 3000
8.33 USD
1 year ago
Mar 20, 2023
Sell 186 K USD
Yan Ming
Chief Technology Officer
- 20000
9.29 USD
1 year ago
Mar 07, 2023
Sell 203 K USD
Jiang Wenbin
President and CEO
- 20000
10.13 USD
1 year ago
Feb 24, 2023
Sell 33.2 K USD
Jeanmonod Patrik
Chief Financial Officer
- 3000
11.05 USD
1 year ago
Feb 21, 2023
Sell 219 K USD
Yan Ming
Chief Technology Officer
- 20000
10.94 USD
1 year ago
Feb 08, 2023
Sell 12.1 K USD
Yan Ming
Chief Technology Officer
- 897
13.53 USD
1 year ago
Feb 07, 2023
Sell 264 K USD
Jiang Wenbin
President and CEO
- 20000
13.19 USD
1 year ago
Feb 03, 2023
Sell 14.6 K USD
Yan Ming
Chief Technology Officer
- 1081
13.5 USD
1 year ago
Feb 03, 2023
Sell 149 USD
Yan Ming
Chief Technology Officer
- 11
13.51 USD
1 year ago
Jan 24, 2023
Sell 38.7 K USD
Jeanmonod Patrik
Chief Financial Officer
- 3500
11.05 USD
1 year ago
Jan 19, 2023
Sell 221 K USD
Yan Ming
Chief Technology Officer
- 20000
11.03 USD
1 year ago
Jan 09, 2023
Sell 213 K USD
Jiang Wenbin
President and CEO
- 20000
10.66 USD
1 year ago
Dec 27, 2022
Sell 34.2 K USD
Jeanmonod Patrik
Chief Financial Officer
- 3500
9.77 USD
1 year ago
Dec 19, 2022
Sell 208 K USD
Yan Ming
Chief Technology Officer
- 20000
10.38 USD
1 year ago
Dec 07, 2022
Sell 237 K USD
Jiang Wenbin
President and CEO
- 20000
11.86 USD
1 year ago
Nov 25, 2022
Sell 50 K USD
Jeanmonod Patrik
Chief Financial Officer
- 3500
14.3 USD
1 year ago
Nov 21, 2022
Sell 293 K USD
Yan Ming
Chief Technology Officer
- 20000
14.66 USD
2 years ago
Nov 14, 2022
Sell 235 K USD
Ball Jack
Director
- 16000
14.69 USD
2 years ago
Nov 07, 2022
Sell 295 K USD
Jiang Wenbin
President and CEO
- 20000
14.76 USD
2 years ago
Oct 24, 2022
Sell 53.1 K USD
Jeanmonod Patrik
Chief Financial Officer
- 3500
15.16 USD
2 years ago
Oct 19, 2022
Sell 288 K USD
Yan Ming
Chief Technology Officer
- 20000
14.42 USD
2 years ago
Oct 07, 2022
Sell 296 K USD
Jiang Wenbin
President and CEO
- 20000
14.79 USD
2 years ago
Aug 24, 2022
Sell 47.1 K USD
Jeanmonod Patrik
Chief Financial Officer
- 3500
13.45 USD
2 years ago
Aug 18, 2022
Sell 272 K USD
Yan Ming
Chief Technology Officer
- 20000
13.62 USD
2 years ago
Aug 08, 2022
Sell 302 K USD
Jiang Wenbin
President and CEO
- 20000
15.09 USD
2 years ago
Aug 01, 2022
Sell 44.8 K USD
Jeanmonod Patrik
Chief Financial Officer
- 3500
12.8 USD
2 years ago
Jul 19, 2022
Sell 237 K USD
Yan Ming
Chief Technology Officer
- 20000
11.83 USD
2 years ago
Jul 07, 2022
Sell 224 K USD
Jiang Wenbin
President and CEO
- 20000
11.19 USD
2 years ago
Jun 21, 2022
Sell 201 K USD
Yan Ming
Chief Technology Officer
- 20000
10.06 USD
2 years ago
Jun 07, 2022
Sell 215 K USD
Jiang Wenbin
President and CEO
- 20000
10.75 USD
2 years ago
May 18, 2022
Sell 198 K USD
Yan Ming
Chief Technology Officer
- 20000
9.92 USD
2 years ago
May 09, 2022
Sell 160 K USD
Jiang Wenbin
President and CEO
- 20000
8.01 USD
2 years ago
Apr 19, 2022
Sell 207 K USD
Yan Ming
Chief Technology Officer
- 20000
10.34 USD
2 years ago
Apr 07, 2022
Sell 211 K USD
Jiang Wenbin
President and CEO
- 20000
10.54 USD
2 years ago
Mar 21, 2022
Sell 233 K USD
Yan Ming
Chief Technology Officer
- 20000
11.64 USD
2 years ago
Mar 14, 2022
Bought 2.96 M USD
Shah Rajeev M.
director:
+ 241727
12.2659 USD
2 years ago
Mar 15, 2022
Bought 2.96 M USD
RA CAPITAL MANAGEMENT, L.P.
director, 10 percent owner:
+ 241727
12.2659 USD
2 years ago
Mar 14, 2022
Bought 4.22 M USD
RA CAPITAL MANAGEMENT, L.P.
director, 10 percent owner:
+ 342143
12.3455 USD
2 years ago
Mar 09, 2022
Bought 4.31 M USD
Shah Rajeev M.
director:
+ 337492
12.7687 USD
2 years ago
Mar 11, 2022
Bought 4.31 M USD
RA CAPITAL MANAGEMENT, L.P.
Director
+ 337492
12.7687 USD
2 years ago
Mar 10, 2022
Bought 3.33 M USD
RA CAPITAL MANAGEMENT, L.P.
Director
+ 256992
12.9482 USD
2 years ago
Mar 09, 2022
Bought 522 K USD
RA CAPITAL MANAGEMENT, L.P.
Director
+ 40154
12.9938 USD
2 years ago
Mar 04, 2022
Sell 16.5 K USD
Jiang Wenbin
President and CEO
- 1200
13.79 USD
2 years ago
Mar 08, 2022
Bought 3.16 M USD
RA CAPITAL MANAGEMENT, L.P.
Director
+ 245701
12.8614 USD
2 years ago
Mar 07, 2022
Bought 4.26 M USD
RA CAPITAL MANAGEMENT, L.P.
Director
+ 337901
12.6101 USD
2 years ago
Mar 04, 2022
Bought 827 K USD
Shah Rajeev M.
director:
+ 63662
12.9941 USD
2 years ago
Mar 04, 2022
Bought 827 K USD
RA CAPITAL MANAGEMENT, L.P.
Director
+ 63662
12.9941 USD
2 years ago
Mar 02, 2022
Bought 1.78 M USD
RA CAPITAL MANAGEMENT, L.P.
Director
+ 138255
12.8908 USD
2 years ago
Mar 01, 2022
Bought 3.83 M USD
RA CAPITAL MANAGEMENT, L.P.
Director
+ 294864
12.9765 USD
2 years ago
Feb 28, 2022
Bought 113 K USD
RA CAPITAL MANAGEMENT, L.P.
Director
+ 8746
12.9694 USD
2 years ago
Feb 25, 2022
Bought 247 K USD
RA CAPITAL MANAGEMENT, L.P.
Director
+ 18991
12.9903 USD
2 years ago
Feb 24, 2022
Bought 2.43 M USD
RA CAPITAL MANAGEMENT, L.P.
Director
+ 186467
13.031 USD
2 years ago
Feb 23, 2022
Bought 2.88 M USD
RA CAPITAL MANAGEMENT, L.P.
Director
+ 214922
13.4147 USD
2 years ago
Feb 22, 2022
Sell 269 K USD
Yan Ming
Chief Technology Officer
- 20000
13.44 USD
2 years ago
Feb 22, 2022
Bought 2.89 M USD
RA CAPITAL MANAGEMENT, L.P.
Director
+ 214922
13.4563 USD
2 years ago
Feb 18, 2022
Bought 2.35 M USD
RA CAPITAL MANAGEMENT, L.P.
Director
+ 166229
14.1154 USD
2 years ago
Feb 17, 2022
Bought 2.46 M USD
RA CAPITAL MANAGEMENT, L.P.
Director
+ 166229
14.7824 USD
2 years ago
Feb 16, 2022
Bought 2.49 M USD
RA CAPITAL MANAGEMENT, L.P.
Director
+ 166200
14.9782 USD
2 years ago
Feb 15, 2022
Bought 2.49 M USD
RA CAPITAL MANAGEMENT, L.P.
Director
+ 166200
14.9851 USD
2 years ago
Feb 14, 2022
Bought 2.45 M USD
RA CAPITAL MANAGEMENT, L.P.
Director
+ 166229
14.7202 USD
2 years ago
Feb 10, 2022
Sell 221 K USD
Yan Ming
Chief Technology Officer
- 14706
15.01 USD
2 years ago
Feb 10, 2022
Sell 81.4 K USD
Yan Ming
Chief Technology Officer
- 5294
15.37 USD
2 years ago
Feb 07, 2022
Sell 288 K USD
Jiang Wenbin
President and CEO
- 20000
14.4 USD
3 years ago
Jul 27, 2021
Bought 47 M USD
RA CAPITAL MANAGEMENT, L.P.
Director
+ 2762786
17 USD
3 years ago
Jul 27, 2021
Bought 3.18 M USD
RA CAPITAL MANAGEMENT, L.P.
Director
+ 187214
17 USD
3 years ago
Jul 22, 2021
Bought 32.3 K USD
Barnett Valerie
General Counsel
+ 1900
17 USD
3 years ago
Jul 22, 2021
Bought 51 K USD
Ball Jack
Director
+ 3000
17 USD
3 years ago
Jul 22, 2021
Bought 85 K USD
Dion Gisele
Director
+ 5000
17 USD
3 years ago
Jul 22, 2021
Bought 25.5 K USD
Poirson Allen
SVP Marketing and Corp. Dev.
+ 1500
17 USD
7. News
Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter FREMONT, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) has introduced an Enhanced Small Particle (ESP™) Detection Option for its Cytek Aurora™ CS system. globenewswire.com - 1 week ago
Cytek Biosciences, Inc. (CTKB) Q3 2024 Earnings Call Transcript Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q3 2024 Earnings Conference Call November 5, 2024 4:30 PM ET Company Participants Paul Goodson - Investor Relations Wenbin Jiang - Chief Executive Officer William McCombe - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Brendan Smith - TD Cowen Mason Carrico - Stephens John Barnidge - Piper Sandler Andrew Cooper - Raymond James Operator Thank you for standing by. At this time, I'd like to welcome everyone to the Cytek Biosciences' Third Quarter 2024 Earnings Conference Call. seekingalpha.com - 1 week ago
Cytek Biosciences, Inc. (CTKB) Q3 Earnings and Revenues Beat Estimates Cytek Biosciences, Inc. (CTKB) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to earnings of $0.01 per share a year ago. zacks.com - 1 week ago
Cytek® Biosciences Brings Full Spectrum Profiling™ (FSP™) Technology to the Forefront at Major Clinical Conferences in the U.S. and Europe FREMONT, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) is set to elevate its presence at this year's premier clinical industry events across the globe. globenewswire.com - 1 month ago
Cytek Announces Resignation of Chief Operating Officer Chris Williams FREMONT, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Chief Operating Officer, Chris Williams, will resign his position effective September 27, 2024, to accept a CEO position at another company. Cytek has chosen not to replace the COO position, opting instead to restructure the organization to create a flatter, more efficient management structure. globenewswire.com - 2 months ago
Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility FREMONT, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that its San Diego reagent manufacturing facility has been awarded EN ISO 13485:2016 Quality Management System (QMS) certification. globenewswire.com - 2 months ago
Cytek Biosciences, Inc. (CTKB) Q2 2024 Earnings Call Transcript Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Paul Goodson - Investor Relations Wenbin Jiang - Chief Executive Officer William McCombe - Chief Financial Officer Conference Call Participants Operator Thank you for standing by. My name is Luella, and I will be your conference operator today. seekingalpha.com - 3 months ago
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Lags Revenue Estimates Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.01 per share a year ago. zacks.com - 3 months ago
Cytek® Biosciences Automates Panel Design with New Intelligent Algorithm Cytek has developed a revolutionary tool to automate panel design. SpectroPanel is an intelligent algorithm that suggests optimized panels in minutes. globenewswire.com - 3 months ago
Cytek Biosciences (CTKB) Moves 5.1% Higher: Will This Strength Last? Cytek Biosciences (CTKB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. zacks.com - 4 months ago
Cytek Biosciences to participate at the Goldman Sachs 45th Annual Global Healthcare Conference FREMONT, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, FL. globenewswire.com - 5 months ago
1-Laser and 2-Laser 6-Color TBNK Reagents from Cytek® Biosciences Approved for Clinical Use in China FREMONT, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that its 1-laser and 2-laser 6-color TBNK reagent cocktails have received China National Medical Products Administration (NMPA) approval for clinical diagnostic use on the Cytek® Northern Lights™-Clinical (NL-CLC™) cell analysis systems in hospitals, laboratories and clinics across China. globenewswire.com - 5 months ago
8. Profile Summary

Cytek Biosciences, Inc. CTKB

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 766 M
Dividend Yield 0.00%
Description Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Contact 47215 Lakeview Boulevard, Fremont, CA, 94538 https://cytekbio.com
IPO Date July 23, 2021
Employees 645
Officers Dr. Allen B. Poirson Ph.D. Senior Vice President of Business & Corporate Development Dr. Philippe Busque Ph.D. Senior Vice President of Global Sales & Services Mr. Patrik Sebastian Jeanmonod Head of Corporate Development Analytics Dr. Wenbin Jiang Ph.D. President, Chief Executive Officer & Chairman of the Board Ms. Valerie T. Barnett J.D. Chief Legal Officer & Corporate Secretary Mr. William D. McCombe Chief Financial Officer Dr. Ming Yan Ph.D. Chief Technology Officer & Director